Novartis Loses $30 Billion Because Science Is Hard

Novartis dropped 9% on Tuesday. Three drug trials failed. Not one. Not two. Three.

The del-desiran trial led the parade of disasters, but two other experimental drugs also face-planted in late-stage studies. Investors who thought pharmaceutical companies just print money by charging $400 for aspirin learned that sometimes you have to actually invent medicine that works. Brutal lesson. The stock erased roughly $30 billion in market value because apparently Wall Street expected a company that gambles billions on molecules to bat a thousand.

Here's what kills me. Retail traders saw Novartis trading at all-time highs in April and thought, "Yes, this Swiss conglomerate with a 150-year history definitely won't have any setbacks in its pipeline of experimental treatments for diseases we can't pronounce." They bought calls. They posted rocket emojis. They explained to their wives that European pharma was a safe play.

Then the trial data came out and those same guys are now screaming about market manipulation because their $200 positions got vaporized. They're writing fifteen-paragraph Reddit posts about how the FDA is corrupt and clinical endpoints are rigged. Nobody told them that drug development has a failure rate higher than their own personal relationships.

Technical analysis says Novartis is testing support at the 50-day moving average. Fundamental analysis says three drugs didn't work and the company wasted years of research. Both analyses are useless. The stock will go wherever it goes based on whether the next trial succeeds or whether another executive gets indicted for lying about efficacy data.

But sure, check the RSI. That'll tell you if cancer drugs work.

Photo by on Unsplash